Ninety analogues of suramin have been examined for their ability to inhibit the exogenous reverse transcriptase (RT) of human immunodeficiency virus type I (HIV-I). Of these compounds, 57 inhibited the poly(rC)-oligo(dG)-dependent RT activity. Three classes of dose-response curves could be discriminated. Allocation of a compound to one class did not correspond with obvious structural features. Twentyfour substances were superior to suramin in our RT inhibition assay. The RTinhibitory activity of these compounds did not correlate with their effect against filariae or trypanosomes. Preliminary antiviral evaluation in susceptible human T cells inoculated with HIV-I demonstrated in vitro therapeutic efficacy for some compounds with lower drug-related cellular toxicity than suramin. Certain structural features relevant for the RT-inhibitory effect of these compounds were recognized. Predictions are made for the design of more effective RT inhibitors. Such compounds will help to understand the molecular mechanism of reverse transcription and might be useful in the therapy of retroviral infections.
INTRODUCTION
Retroviruses cause a wide spectrum of diseases in animals including various types of malignancies and non-malignant diseases such as immunodeficiency (Teicb, 1982) . Recently, retroviruses have been isolated from patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related symptoms, and designated lymphadenopathy-associated virus (LAV) (Barr6-Sinoussi et aL, 1983) , human T-lymphotropic virus type III (HTLV-III) or AIDS-related virus (ARV) (Levy et al., 1984) . These viruses have since been collectively designated human immunodeficiency viruses (HIV). Inhibitors of the reverse transcriptase (RT) have played a role in studying the mechanism of action of RT (Smith & Gallo, 1974; Chandra et al., 1985) . In addition, they have opened the possibility of interfering specifically with viral integration (Verma, 1977; De Clercq & Balzarini, 1985) . Thus RT inhibitors may be used for prevention and treatment of retrovirus-induced diseases.
Much effort has been invested to develop antiviral chemotherapy (Chandra et al., 1984; De Clercq & Balzarini, 1985) . An ideal therapeutic agent blocks virus replication specifically leaving vital host cell functions intact. To find such compounds several different routes have been followed. Nucleotides have been modified, e.g. ribavirin containing 1,2,4-triazole as a base (McCormick et al., 1984) . Other approaches have included the use of acyclic base analogues, e.g. acyclovir which is particularly effective against herpes simplex virus (Field & Phillips, 1983) , modified nucleoside analogues (De Clercq et al., 1986; Aoyama et al., 1985) , pentose-modified nucleosides, e.g. 2',3'-dideoxycytosine , and the most promising agent at the moment 3'-azido-3'-deoxythymidine (AZT) Furman et al., 1986 ; HTLV-IIIB were harvested by low speed centrifugation at 4 °C. The supernatant was centrifuged for 30 min at 15 000 g at 4 °C to remove cell debris. Virus was pelleted by centrifugation for 2.5 h at 32000 g at 4 °C. Pellets were washed with phosphate-buffered saline pH 7.2 (PBS) by a further centrifugation step and resuspended in PBS. Finally the virus was centrifuged for 70 rain at 50000g at 4 °C and the pellet was carefully resuspended in 2-5 ml of sterile PBS. The protein concentration was determined according to the method of Lowry et al. (1951) . An equal volume of glycerol (highly purified grade) was added to the purified virus. Under these conditions, virus could be stored unfrozen at -20 °C for up to 2 months without significant loss of enzyme activity.
All drugs were tested at least in triplicate and 57 of the 90 compounds were found to have antiviral properties. Thirty-two of these were tested with a virus preparation having asp. act. of 10 pmol d G MP incorporation per ~tg viral protein in 45 min at 42 °C. The other 25, suramin, and several controls were investigated using a second virus preparation with a specific activity of about 5 pmol dGMP incorporation per gg viral protein. Both viral preparations contained about 1 mg protein per ml. It seemed likely that the low sp. act. of the second preparation was due to a partial loss of RT activity during the large scale virus purification.
RT assay. RT assays were done according to standard procedures (Novak et al., 1979; Poiesz et al., 1980; Hoffmann et al., 1985) with slight modifications to achieve optimal conditions for HIV-I RT. The final concentration was adjusted to contain 0.6~ Triton X-100 and 25 mi-Mg 2÷ (Schneider et al., 1987) . The salt concentration was kept low (30 mM-KCI) as many compounds showed different inhibition characteristics at higher salt concentrations. One gg poly(rC).oligo(dG) (Pharmacia) was added as template primer per 50 ~1 of reaction mixture. The sp. act. of the [32P]dGTP was 3000 Ci/mmol (Amersham Buchler). In the reaction mixture the sp. act. was about 6 x 103 c.p.m./pmol.
Suramin analogues were dissolved in 10 mM-Tris HCI pH 7.5, and dilutions from freshly prepared stock solutions were added to the reaction mixture at 0 °C. The RT reaction was run at 42 °C for 45 min. The viral protein concentration per assay was about 1 p_g. The test was normalized to obtain linear kinetic conditions for all compounds. Reactions were stopped by adding 20 pl 10K SDS to a 50 ~tl sample volume. These were then adsorbed to Whatman DEAE-cellulose paper (DE-81), dried, and washed extensively with 0-5 ~ dibasic sodium phosphate buffer. The final glycerol concentration of about 1 ~ in the assay was stimulating rather than inhibitory for the activity (Hoffmann et al., 1985) . Concentrations of suramin derivatives in the assay ranged from 5 gg to up to 1000 p.g/ml. The dose-response curve was plotted for each inhibitor and its 50~ inhibitory dose (IDs0) was extrapolated from the curve, Synthesis and properties ofsuramin derivatives. All compounds investigated were related to suramin (Fig. I ). Suramin is a symmetrical molecule which can be described by a schematic structure (1, Table 1) composed of three types of elements: a highly acidic group A, an aminobenzoyl residue B and a central urea group C. In Fig. 1 these structural elements are indicated in the formula of suramin. If compounds have a symmetrical structure like suramin it is sufficient to give one half of the molecule for an unambiguous description. Thus the chemical code for suramin is Aa-Bb-Ba-Cc (instead of Aa-Bb-Ba-Cc-Ba-Bb-Aa). The compounds investigated had the schematic structures (1), (2), (3) or (4) ( 
A-B C * Highly acidic group (A), aminobenzoyl group (B) and central group (C) are the structural elements of the compounds: (1) and (2) are symmetrical molecules; (3) and (4) are non-symmetrical molecules, precursors in the synthesis of (1) and (2) respectively.
In the suramin analogues, the partial structures A, B and C have been systematically altered. The 1-aminonaphthalene-4,6,8-trisulphonic acid residue A has been replaced by aromatic and aliphatic sulphonic, phosphonic, or carbonic acids. B has been replaced by other substituted benzoyl groups. The central urea group has also been varied. The chemical compositions of these structural elements are given in Table 2 . With the data from Table 2 each compound tested can be described by a short code name, e.g. suramin by Aa-Bb-Ba-Cc.
Synthesis, analytical data, antifilarial and trypanocidal activities of these suramin analogues have been published elsewhere (Nickel et al., 1986; Holzmann et al., 1985) . All tested compounds were sodium salts.
Cell culture assay. A modification of a recently described assay for neutralizing antibodies was used for the evaluation of antiviral activity in vitro (Harada et al., 1986) . In summary, MT4 cells, a human HTLV-I-bearing cell line (Miyoshi et al., 1982) , which is susceptible to HIV-I (Harada et al., 1985a, b) were incubated with HIV-I and the compounds to be tested. In the case of antiviral activity the virus-dependent cytopathogenicity was reversed, allowing cell growth, which was monitored by thymidine incorporation into the cells (Harada et al., 1986) . Compound-related cellular toxicity was estimated by incubating MT4 cells in the absence of HIV-I.
RESULTS

Chemical modification of suramin results in more potent HIV-I RT inhibitors
Inhibitory dose-response curves for 90 suramin derivatives have been established. As template-primer for RT assays we used poly(rC), oligo(dG), known to be specific for retroviral RT (Baltimore & Smaler, 1971 ; Poiesz et al., 1980) . The enzyme originated from highly purified HTLV-IIIB-infected Jurkat cells (Wendler et al., 1987) . To test for contamination with cellular enzymes poly(rA), oligo(dT) and poly(dA).oligo(dT) were also used as the primer-template (Sarngadharan et al., 1972 (Sarngadharan et al., , 1978 Poiesz et al., 1980) . According to these tests, the amount of contaminating cellular polymerases was less than 10~o of the total polymerase activity. With poly(rC).oligo(dG), no incorporation of radioactivity from cellular polymerases could be detected. 
* C is -NH-for the benzoyl residues B adjacent to group A in compounds of type (1) and (3) (Table 1) , in all other cases the central unit C.
t Compounds with central units Cc to Ci are symmetrical molecules with two identical residues attached to C. In compounds with the central unit Cj four identical residues are attached to Cj.
Fifty-seven compounds inhibited the RT activity. Among them, 14 showed an IDs0 below that of suramin (IDso 52 gg/ml) using the first virus preparation I (sp. act., approx. 10 pmol/~g viral protein) and an additional 10 examined with the second virus preparation were more effective than suramin (IDso 48 ~tg/ml) Of the inhibitory compounds nearly half were more potent than suramin and 10 were equally effective. One compound (NF 067) was tenfold more effective than suramin and six were fourto fivefold better (Tables 3 and 4) .
Three types of dose-response curves
Three characteristic types of dose-response curves were observed (Fig. 2 ). These were designated class I, II/I and II. Whether these classes reflect different mechanisms of RT inhibition remains to be determined. However, similar dose response characteristics were obtained with HTLV-I and simian immunodeficiency virus from rhesus monkey (K.D. Jentsch, G. Hunsmann & P. Nickel, unpublished results). Class I agents (20 in all) initiated an immediate decrease of the enzyme activity. Class II/I derivatives showed a biphasic reaction. After a rather slow initial inhibitory effect, a sharp reduction in the RT activity was observed. Eighteen compounds were classified in this group. When some of the these drugs were examined with the less active virus preparation, a shift from class I to class II/I was observed. This change may have been caused by binding of the inhibitor to inactive RT or to other proteins in the preparation. Further experiments are needed to clarify whether these compounds bind to proteins other than RT. Finally, class II derivatives (18 compounds) were distinguished by a shoulder or plateau before the inhibition began at higher concentrations. Their IDs0 ranged from 22 ~tg/ml (NF 213) up to 800 ~tg/ml for NF 078, the compound with the highest IDso. * TE, Therapeutic efficiency in vitro is given as the lowest effective concentration of the compounds, at which complete prevention of virus-dependent cytopathogenicity was observed.
t Tox, Toxicity in vitro, given as the concentration at which cell growth was impaired in the absence of HIV.
Mol. wt. of the sodium salt. § 3dentical to suramin. ]l Concentration gtl/ml) corresponding to maximum curvature at shoulder of inhibition curve.
A correlation between the length of the plateau and the IDso was obvious (Tables 3 and 4) . In order to test the hydrolytic stability of the compounds, aqueous solutions were examined after freezing and thawing up to 10 times. This treatment had no obvious influence on the inhibitory activity of the compounds. Nevertheless only fresh solutions were used for the inhibition assays.
Several structural and enzymic features influence HIV-I RT inhibition
The influence of salt concentration and dependence on divalent cations (Mg z+ or Mn 2+) also seemed to play an important role. Substances with a very sharp salt optimum (like NF 058, NF 223, NF 103, NF 068, NF 217 and NF 100) were smaller molecules than suramin, and showed either no inhibitory effect or had very high IDso values with Mn 2+ as the divalent cation (NF 068, NF 058), whereas some large ureas [like NF 031, NF 037 and NF 060 (suramin)] had a rather broad salt optimum within the investigated range from 10 to 120 mM-KC1. These latter compounds showed RT inhibition with both Mg 2+ and Mn -'+. Table 3 for details.
Inhibition of virus-dependent cytopathogenicity
In Tables 3 and 4 the lowest concentrations yielding complete reversion of virus-induced cytopathogenicity are given for individual compounds. In addition the concentrations showing drug-related cellular toxicity are listed. A comparison of the therapeutic and toxic concentrations allows an estimate of an in vitro therapeutic index. This index was very high for NF 110, which should guide further synthetic strategies. DISCUSSION Earlier, De Clercq (1979) had investigated the effect of suramin on retroviral RT, and could demonstrate that suramin competitively inhibits poly(rA).oligo(dT) binding to the enzyme. Based on these results, studies in vitro (Mitsuya et al., 1984) and clinical studies have been carried out with the aim of investigating the effect of suramln in HIV-I infections. We have used poly(rC)-oligo(dG) as template-primer for two reasons: (i) it is stable at 42 °C in low salt solutions, which are necessary conditions for testing the different compounds, whereas in low salt concentrations poly(rA), oligo(dT) would not be stable (Waters et al., 1974; Modak et al., 1977) ; (ii) it was important that enzyme assays were stable over longer times so that we could quantitatively compare the relative inhibition by the drugs. We have found (W. Lfike et al., personal communication) that the HIV-I reverse transcriptase activity measured with poly(rA)-oligo(dT) decreases within days. In contrast, enzyme activity determined with poly(rC).oligo(dG) as a template-primer is much more stable. This observation probably explains the different template-primer preferences described for HIV-I RT and isolated HIV-I RT by several authors (Hoffmann et al., 1985; Chandra et aL, 1986; Vrang & 0berg, 1986; di Marzo Veronese et al., 1986; Cheng et al., 1987) Three different doseresponse curves have been observed with 57 suramin analogue RT inhibitors. These active RT inhibitors were detected among 90 structurally modified derivatives of suramin.
Interestingly there is no clear relationship yet between the chemical structure and the different kinetic types of enzyme inhibitors. However, our results indicate that the classification into these three groups may depend upon the viral source of the enzyme tested.
The inhibition of HIV-I RT is much less sensitive to structural modifications of suramin than is the trypanocidal or antifilarial activity. Moreover, the structure-activity relationships are totally different from those found for the latter two activities. All compounds mentioned in this paper have been synthesized with the aim of finding antifilarial drugs superior to suramin for the treatment of onchocerciasis (Nickel et aL, 1986) . Suramin has also been widely used for the treatment of trypanosomiasis. Very small variations of the suramin molecule lead to a sharp decrease of its trypanocidal activity. Thus the suramin analogue Aa-Ba-Ba-Cc in which the two methyl groups of suramin have been replaced by hydrogen has only about 5 ~ of the trypanocidal activity of suramin, whereas the toxicity remains unchanged (Fourneau et al., 1924) .
Although for the antifilarial activity of suramin analogues the structure-activity relationships are not the same as for trypanocidal activity, the activity is also very sensitive towards small structural variations of the suramin molecule (Nickel et al., 1986) .
Structural features like overall molecular size, acidity, size of the central group C and certain substitution patterns that determine the RT inhibitory activity of a compound could be defined. Group A in molecules of types (1) to (4) (Table 1) must be a strong acid. All compounds in which group A of suramin had been replaced by aliphatic (aspartic, glutamic, imino-bis acetic acid) or aromatic (aminobenzoic acids) carbonic acids were inactive. Analogues containing aliphatic sulphonic acids (Ag) or aliphatic phosphonic acids (A1) were also inactive.
The molecular size seemed to be more important for a high inhibitory activity than the substitution pattern. In corresponding pairs of compounds (small ureas containing two benzoyl residues and big ureas containing four benzoyl residues) the small ureas showed in most cases a significantly higher activity than the big ureas (Table 5) . One exception was the pair NF 217 (Aa-Bj-Cc)/NF 218 (Aa-Bj-Ba-Cc). In this case the big urea had a significantly higher inhibitory activity than the small one. This could be due to steric hindrance of the two o-methyl groups in the benzoyl residue Bj. Steric factors could also be of importance for the activity of all suramin analogues in which the methyl groups of suramin had been replaced by larger substituents. All of these latter analogues were less active than suramin.
The ratio between molecular size and number of acid groups in parts of the molecule seems to be important for the inhibitory activity. A sulphanilic acid analogue of suramin (Ad-Bb-Ba-Cc), having only two sulphonic acid groups was inactive, but suramin analogues containing aniline-2,4-disulphonic acid (NF 065 Ae-Bb-Ba-Cc) or aniline-2,5-disulphonic acid (NF 063 Af-Bb-BaCc), having four sulphonic acid groups, were both active. A compound containing four sulphanilic acid residues (Ad-Cj) (NF 110) was also among the most active inhibitors. This again indicates that molecular size and number of acidic groups are more important than the substitution pattern.
The synthesis of phosphonic acid analogues of suramin was planned with the idea that suramin may bind to nucleic acids or nucleotides. If this were true, phosphonic acids could be even better competitors for the binding sites. The molecular size is important for the inhibitory activity of phosphonic acid analogues. Thus, the small urea Ai-Cc (NF 161) was inactive whereas the larger urea Ai-Ba-Cc (NF 067) was active.
Two of the most active compounds (NF 031 Ab-Bk-Bk-Cc, NF 013 Ab-Bk-Cc) are derivatives of 1-aminonaphthalene-3,6,8-trisulphonic acid, an isomer of the trisulphonic acid in suramin. These two compounds showed no trypanocidal or antifilarial activities. Therefore, no further syntheses have been done in this series. The same is true for other isomers or analogues of the acid Aa. Further synthesis in this field may lead to highly inhibitory compounds.
The difference in antiviral potency between the data obtained when measuring RT activity and when measuring inhibition of viral cytopathogenicity may be explained e.g. by different abilities of individual substrates to penetrate cell membranes or by enzyme degradation of the compounds. Compared to antiviral compounds currently used in clinical trials such as AZT the in vitro therapeutic index of suramin-related compounds is rather low; however, due to the apparent low toxicity of some, they might still be considered as potential therapeutic agents, and might help to direct strategies for the synthesis of new agents.
